Generic Name and Formulations:
Liothyronine sodium 5mcg, 25mcg, 50mcg; tabs.
Indications for CYTOMEL:
Hypothyroidism: initially 25mcg daily; may increase by up to 25mcg every 1–2 weeks; usual maintenance 25–75mcg daily. Myxedema, simple goiter: initially 5mcg daily; may increase by 5–10mcg daily every 1–2 weeks to 25mcg daily, then may increase by 5–25mcg every 1–2 weeks (myxedema) or by 12.5 or 25mcg daily every 1–2 weeks (simple goiter). Maintenance: myxedema: 50–100mcg/day; simple goiter: 75mcg/day.
Initially 5mcg daily; may increase by 5mcg daily every 3–4 days. Cretinism: maintenance dose: <1yr: 20mcg/day. 1–3 yrs: 50mcg/day. >3yrs: as adult.
Initially 5mcg daily; may increase by 5mcg every 1–2 weeks.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis.
Not for treatment of obesity or infertility (unless with hypothyroidism). Cardiovascular disease, angina, elderly: use lower initial dose. Adrenocortical insufficiency. Diabetes. Monitor for craniosynostosis in infants. Pregnancy (Cat.A). Nursing mothers.
Monitor oral anticoagulants, hypoglycemics, digoxin. Estrogens affect thyroid function tests. Monitor for hypertension with ketamine. Toxicity with larger doses of sympathomimetics (eg, anorectics).
Hyperthyroidism, transient hair loss in children.
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy